Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-05230907 in Intracerebral Hemorrhage
NCT02687191Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Nov 2016
- Primary completion
- Jan 2018
- Modality
- Blood Coagulation Factors
- Countries
- 4
01
Overview
Phase 1, open-label trial of PF-05230907 in intracerebral hemorrhage (ICH) (15 cohorts), sponsored by Pfizer. Primary endpoints: Treatment-Emergent Thromboembolic and/or Ischemic Events, Treatment-Emergent Serious Adverse Events and 8 more. Started Nov 2016; status: terminated.
02
Drugs
PF-05230907
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on NCT02687191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02687191.